

GILUPI Announces Attendance and Exhibition at the ACTC Conference 2019

GILUPI GmbH announced today that the company is a sponsor of the 4th ACTC “Liquid Biopsy: Latest Advances and Future Challenges” meeting. The conference is held in Corfu, Greece from October 2nd to 5th 2019.

The main aim of the meeting is to bring together researchers from academia, clinics and industry to present, discuss and share the latest information on liquid biopsy. State-of-the-art research on the latest technical advancements in the isolation and molecular characterization of CTCs, ctDNA, miRNAs and exosomes will be presented in selected oral presentations and poster sessions.

Results generated with the GILUPI CellCollector® are presented by several research groups throughout the meeting. For example, a presentation entitled ‘Combination of *in vivo* CTC isolation and *in situ* Padlock probe technology for mRNA detection’ will be presented by researchers from the Center for Biomarker Research in Medicine (CBmed), Graz, the University Clinic Halle, Germany and the Gottfried Schatz Research Center at the Medical University Graz.

“We are proud to be a sponsor of this important scientific meeting and are looking forward to discussing the latest clinical studies and developments in CTC research with some of the leading experts in the field of liquid biopsy.” commented Dr. Christian Jurinke, CEO of GILUPI GmbH.

GILUPI will have a booth in the exhibition area to interact with the attendees and scientists will be available for questions and discussions during the exhibition hours.

About GILUPI

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the *in vivo* isolation of rare cells from the blood circulation. Currently, the main focus is the diagnostics market for cancer.

The concept of personalized medicine becomes increasingly important in oncology. The identification of the right drug for the individual patient is today's challenge in clinical practice. To address this medical need, the GILUPI CellCollector® is used to enrich rare cells by immuno-capture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers in various cancer types. Isolated cells can be characterized and analyzed down to a molecular level with immunostaining, DNA- or RNA-based methods.

The GILUPI CellCollector® is the first *in vivo* CTC isolation product that is CE approved.

For further information visit www.gilupi.com